6 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | $8M | -$300M | 0.0% | -6235.7% | -$759M | — | $1.4B |
| 2025 | $29M | -$172M | 0.0% | -3453.3% | -$844M | — | $2.7B |
| 2024 | $33M | $4.3B | 0.0% | 13746.9% | -$767M | $431M | $6.5B |
| 2023 | $32M | -$1.0B | 0.0% | -2875.9% | -$856M | $376M | $1.7B |
| 2022 | $55M | -$845M | 0.0% | -2444.8% | -$695M | $210M | $2.1B |
| 2021 | $24M | -$809M | 0.0% | -4500.5% | -$558M | $170M | $2.1B |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3M | $303M | 0.0% | 16477.8% | -$165M | — | $1.4B |
| Dec '25 | $2M | -$266M | 0.0% | -16966.1% | -$192M | — | $1.5B |
| Sep '25 | $2M | -$114M | 0.0% | -19492.9% | -$194M | — | $1.2B |
| Jun '25 | $2M | -$223M | 0.0% | -13130.0% | -$208M | — | $1.2B |
| Mar '25 | $8M | -$206M | 0.0% | -3764.4% | -$173M | — | $2.7B |
| Dec '24 | $9M | $169M | 0.0% | -3042.6% | -$209M | — | $2.0B |
| Sep '24 | $4M | -$230M | 0.0% | -7636.0% | -$268M | — | $2.0B |
| Jun '24 | $8M | $95M | 0.0% | -1279.5% | -$194M | $312M | $5.7B |
| Mar '24 | $9M | -$151M | 0.0% | -2293.1% | -$109M | $431M | $6.5B |
| Dec '23 | $16M | $5.1B | 0.0% | 32948.6% | -$211M | $403M | $6.7B |
| Sep '23 | $4M | -$304M | 0.0% | -5863.2% | -$197M | $389M | $1.4B |
| Jun '23 | $22M | -$292M | 0.0% | -1278.3% | -$250M | $385M | $1.4B |
| Mar '23 | $27M | -$34M | 0.0% | -855.4% | -$181M | $376M | $1.7B |
| Dec '22 | $17M | -$352M | 0.0% | -2217.2% | -$223M | $375M | $1.5B |
| Sep '22 | $13M | -$292M | 0.0% | -2240.2% | -$193M | $376M | $1.6B |
| Jun '22 | $4M | -$332M | 0.0% | -6536.4% | -$260M | $417M | $1.9B |
| Mar '22 | $9M | -$270M | 0.0% | -2892.8% | -$154M | $210M | $2.1B |
| Dec '21 | $24M | -$285M | 0.0% | -1010.7% | -$275M | $204M | $2.2B |
| Sep '21 | $14M | -$208M | 0.0% | -4893.3% | -$123M | $200M | $2.5B |
| Jun '21 | $8M | -$82M | 0.0% | -1996.0% | -$144M | $186M | $2.0B |
How the market has priced ROIV against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Roivant Sciences Ltd.'s revenue has declined 19.1% per year. These are computed facts, not advice.
As of FY2026, Roivant Sciences Ltd. reported — of total debt against $1.4B of cash.
In FY2026, gross margin was —, operating margin -6235.7%, and net margin -3629.2%.
As of Jun '26, Roivant Sciences Ltd. traded at a price-to-earnings ratio of about 1.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.